Chesapeake IRB Announces Acquisition of Goodwyn IRB
Combined Assets Expand Expertise and Reach
Chesapeake IRB, announced it has completed the acquisition of Goodwyn IRB.
Goodwyn IRB, headquartered in Cincinnati, Ohio, and Chesapeake IRB, headquartered in Columbia, Maryland are providers of federally mandated institutional review board (“IRB”) services to pharmaceutical, biotech and medical device companies, universities, academic medical centers, hospital systems, governmental entities and others required to use IRB services to assure the protection of rights and the welfare of human subjects participating in research.
Felix Gyi, Founder and CEO of Chesapeake IRB, said, “We are excited to acquire Goodwyn IRB. Their operational expertise and commitment to human protection mirrors our own and will be an asset as we continue to build Chesapeake’s market presence as a leading independent IRB.”
Ellen Kelso, Founder and CEO of Goodwyn IRB, said “Goodwyn IRB is very pleased to be owned by Chesapeake IRB. We will share best practices across the firms while continuing to offer exceptional institutional review board services and human protection to our clients. They will now be able to utilize Chesapeake’s Center for IRB Intelligence (CIRBI) and have real time 24x7 access to all study documents.”
Elyse Summers, President and CEO, Association for the Accreditation of Human Research Protection Programs, commented “AAHRPP is delighted that two AAHRPP accredited, highly respected, independent IRBs have found the common ground of accreditation as a leverage point to create an enhanced organization.”
Goulston & Storrs served as counsel to Chesapeake IRB. Vorys served as counsel to Goodwyn IRB. Madison Capital Funding LLC provided financing to support the transaction.
For questions regarding Chesapeake IRB or Goodwyn IRB please contact:
Ruth Boulter – Vice President Business Development, Chesapeake IRB (609) 731-8786
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
